The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach

DSpace/Manakin Repository

The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach

Citable link to this page

 

 
Title: The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach
Author: Korf, Bruce; Ahmadian, Reza; Allanson, Judith; Aoki, Yoko; Bakker, Annette; Wright, Emma Burkitt; Denger, Brian; Elgersma, Ype; Gelb, Bruce D.; Gripp, Karen W.; Kerr, Bronwyn; Kontaridis, Maria Irene; Lazaro, Conxi; Linardic, Corinne; Lozano, Reymundo; MacRae, Calum Archibald; Messiaen, Ludwine; Mulero-Navarro, Sonia; Neel, Benjamin; Plotkin, Scott Randall; Rauen, Katherine A.; Roberts, Amy Elizabeth; Silva, Alcino J.; Sittampalam, Sitta G.; Zhang, Chao; Schoyer, Lisa

Note: Order does not necessarily reflect citation order of authors.

Citation: Korf, Bruce, Reza Ahmadian, Judith Allanson, Yoko Aoki, Annette Bakker, Emma Burkitt Wright, Brian Denger, et al. 2015. The Third International Meeting on Genetic Disorders in the RAS/MAPK Pathway: Towards a Therapeutic Approach. American Journal of Medical Genetics Part A 167, no. 8: 1741–1746. Portico. doi:10.1002/ajmg.a.37089.
Full Text & Related Files:
Abstract: "The Third International Meeting on Genetic Disorders in the RAS/MAPK Pathway: Towards a Therapeutic Approach" was held at the Renaissance Orlando at SeaWorld Hotel (August 2-4, 2013). Seventy-one physicians and scientists attended the meeting, and parallel meetings were held by patient advocacy groups (CFC International, Costello Syndrome Family Network, NF Network and Noonan Syndrome Foundation). Parent and patient advocates opened the meeting with a panel discussion to set the stage regarding their hopes and expectations for therapeutic advances. In keeping with the theme on therapeutic development, the sessions followed a progression from description of the phenotype and definition of therapeutic endpoints, to definition of genomic changes, to identification of therapeutic targets in the RAS/MAPK pathway, to preclinical drug development and testing, to clinical trials. These proceedings will review the major points of discussion.
Published Version: doi:10.1002/ajmg.a.37089
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515140/
Terms of Use: This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:30207916
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters